- Joined
- 27 June 2010
- Posts
- 4,335
- Reactions
- 368
Donaco International to spin out mobile payments and banking technology business
Wednesday, February 26, 2014 by Proactive Investors
Donaco International (ASX: DNA) should trade higher after revealing plans to spin off its mobile technology business, iSentric, into a new company separately listed on the ASX.
Establishing iSentric as a separate ASX-listed company will enable it to receive the proper focus from investors, who have been eager to follow similar businesses operating in this space.
The iSentric business is cashflow positive, based in Kuala Lumpur, and was acquired by Donaco for $8.5 million in scrip in June 2013
iSentric Limited, a mobility services company, provides mobile content distribution, mobile payment aggregation, mobile banking, and bespoke corporate mobility solutions. It operates through three divisions: Digital Payments, Enterprise Mobility, and Digital Content and Services.
ICU came to my attention recently and after initially dismissing it as a basket case based on its historical financials, I then did some more research and realised its a new company and it was more interesting than I first thought.
They operate in SE Asia,
While they are a tiny company, they do look to have fantastic growth and with no debt, cash in hand and a niche market they may just be onto something.
Its definitely a speculative play and my position size reflects that, but if they can deliver anywhere near their expectations in the next 12 months they will be basically trading with an equity valuation that is only 6-8 times earnings.
If you exclude the costs incurred as a result of Indonesian growth within the core iSentric business, the company trades at about 5-6 times earnings (assumes the 2.2m NPAT given for Arte Mobile is correct); and this does not take into account the ~$3m in net cash ($20m market cap currently).
Also worth noting the participation of insiders when it was spun-off from DNA and the subsequent capital raising.
Seems like a typical spin-off mispricing to me - I may be wrong though.
Should get a quarterly statement at the end of this month. Might give a hint as to how the acquisition is progressing.
Without ploughing through the prospectus I couldn't see how ICU intend to make money and what there target markets are.
I couldn't see how ICU intend to make money and what there target markets are.
Current chart starting to look interestingThe story is starting to play out with ICU, I suspect that if they can get a bit of stability in their earnings and cashflow over a few quarters then there will be a significant re-rating.
I have had a parcel in my SMSF for a while and took a small position in it as a trade in my personal portfolio. Its only the second time I have tried to make a short term trade as opposed as investing - and both took several months to get to a price where I could exit with a small profit!! I have learn my lesson and will leave trading to those better suited to it!
I will probably just hold on to both parcels as I actually see them transitioning into an investible business.
long time between drinks.ICU came to my attention recently and after initially dismissing it as a basket case based on its historical financials, I then did some more research and realised its a new company and it was more interesting than I first thought.
They operate in SE Asia,..
While they are a tiny company, they do look to have fantastic growth and with no debt, cash in hand and a niche market they may just be onto something.
.
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?